Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP ‐1 receptor agonism in patients with type 2 diabetes
Authors:
Open Access
- 19 July 2012
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 14 (12) , 1097-1103
Abstract
Aims: Exenatide is a glucagon‐like peptide‐1 receptor agonist shown to improve glycaemic control in patients with type 2 diabetes ( T2DM ). Intermittent exenatide exposure is achieved with the twice‐daily formulation ( ExBID ), while the once‐weekly formulation ( ExQW ) provides continuous exenatide exposure. This integrated, retrospective analysis compared safety and tolerability of ExQW vs. ExBID in patients with T2DM . Methods: Data were pooled from two open‐label, randomized, comparator‐controlled, trials directly comparing ExQW (N = 277) to ExBID (N = 268). Between‐group differences in adverse event ( AE ) and hypoglycaemia incidences were calculated. Incidence over time and duration of selected AEs (nausea, vomiting, and injection‐site‐related AEs ) were also summarized. Results: The most common AEs were nausea, diarrhoea, injection‐site pruritus, and vomiting. Nausea and vomiting occurred less frequently with ExQW vs. ExBID , peaking at initiation ( ExQW ) or at initiation and dose escalation ( ExBID ), and decreasing over time. Few patients discontinued because of gastrointestinal‐related AEs . Injection‐site AEs were more common with ExQW but decreased over time in both groups. No major hypoglycaemia occurred; minor hypoglycaemia occurred with low incidence in patients not using concomitant sulphonylurea, with no difference between ExQW and ExBID . Serious AEs and discontinuations because of AEs were reported with similar frequency in both groups. Conclusions: Both exenatide formulations were generally safe and well‐tolerated, with ExQW associated with less nausea and vomiting but more injection‐site AEs . Continuous vs. intermittent exposure did not impact the overall tolerability profile of exenatide, with no evidence of prolonged duration or worsened intensities of AEs with continuous exposure.Keywords
Funding Information
- Amylin Pharmaceuticals, Inc.
- Eli Lilly and Company
This publication has 27 references indexed in Scilit:
- Encapsulation of Exenatide in Poly-( d,l -Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 DiabetesDiabetes Technology & Therapeutics, 2011
- Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cellsProgress in Biophysics and Molecular Biology, 2011
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesCardiovascular Diabetology, 2011
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple DosingClinical Pharmacokinetics, 2011
- Prophylactic use of anti‐emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open‐label, parallel‐group, single‐dose study in healthy subjectsDiabetic Medicine, 2010
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 WeeksDiabetes Care, 2010
- Augmented Renal ClearanceClinical Pharmacokinetics, 2010
- One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic PatientsDiabetes Care, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurrent Medical Research and Opinion, 2007